General discussion, page-15860

IHL 42X. This is what keeps me invested amongst their other activities and like many here, I am very optimistic about revenue growth and synergy around clinical commercialisation of their treatments particularly OSA. There is an alternative to a CPAP machine and IHL has it. Personally I have family who suffer with OSA, and it is a very serious and difficult condition... Have no doubt IHL is working hard to bring this treatment to market. Below is taken from their website.

Incannex is developing a pill-form, user-friendly treatment for obstructive sleep apnea because the current standard of care treatment, the Continuous Positive Airway Pressure machine, entails poor patient compliance due to severe discomfort.IHL-42X is a proprietary synergistic composition drug comprising low-dose dronabinol (2.5mg), a synthetic form of Tetrahydrocannabinol (THC), and acetazolamide (125mg), a carbonic anhydrase inhibitor.

Results from a phase 2 proof of concept clinical trial undertaken by Incannex, with 44 data points from participants, were published in 2022.

Trial participants in the trial saw a large and statistically significant reduction in the apnea-hypopnea index (AHI) vs placebo.Average apnea hypopnea index (AHI) was reduced from 42.8 to 21.1 events/hour in the IHL-42X arm, a 50.7% reduction in AHI. Furthermore, 60% of participants experienced a greater than 55% reduction in AHI and 25% of treated participants displayed an 80% or greater reduction.

The AHI reduction benefit occurred across the entire night unlike CPAP that are often used for only part of the night due to discomfort experienced by the user.
No serious treatment emergent adverse events were reported during the clinical trial and IHL-42X improved multiple measures of sleep quality vs placebo.IHL-42X improved sleep efficiency, defined as the proportion of time a person is asleep in bed, reduced the number of awakenings per night, and reduced the total minutes the subject was awake during the night.